Although no significance was reached, which could be due to smaller number (only 129) of HER2 positive patients in this study, this may indicate a subtype specific effect of DRAIC in breast cancer and its function in HER2 positive patients need to be investigated further. The gene discussed is ERBB2; the disease is breast cancer.